Compare Ishares Msci Spain ETF (EWP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Recursion Pharmaceuticals Inc — how do they compare? Ishares Msci Spain ETF trades at $62.65, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWP | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $62.66 | $6.79 |
52-Week Low | $47.02 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP is trading at $62.66, up 0.58% with a bullish technical signal driven by strong moving average support. The stock shows mixed momentum with overbought RSI readings but positive ADX trend strength. Recent corporate actions include a $0.92 dividend scheduled for June 2026. European market sentiment remains influenced by ECB policy decisions and energy price volatility.
The stock's outlook balances technical strength against fundamental data gaps. European economic resilience and potential short-squeeze dynamics offer upside, while overbought conditions and geopolitical risks present near-term headwinds. Dividend income provides additional shareholder value, though comprehensive financial metrics are needed for full fundamental assessment.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
